학술논문
Introduction to the Site-specific Etiologic Results From the Pneumonia Etiology Research for Child Health (PERCH) Study.
Document Type
Academic Journal
Author
Deloria Knoll M; From the Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.; Prosperi C; From the Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.; Baggett HC; Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia.; Brooks WA; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.; International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka and Matlab, Bangladesh.; Feikin DR; From the Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.; Hammitt LL; From the Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.; Howie SRC; Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Basse, The Gambia.; Department of Paediatrics University of Auckland, New Zealand.; Kotloff KL; Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.; Madhi SA; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa.; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases Unit, University of the Witwatersrand, Johannesburg, South Africa.; Murdoch DR; Department of Pathology, University of Otago, Christchurch, New Zealand.; Microbiology Unit, Canterbury Health Laboratories, Christchurch, New Zealand.; Scott JAG; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Thea DM; Department of Global Health and Development, Boston University School of Public Health, Boston, Massachusetts.; O'Brien KL; From the Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Source
Publisher: Williams & Wilkins Country of Publication: United States NLM ID: 8701858 Publication Model: Print Cited Medium: Internet ISSN: 1532-0987 (Electronic) Linking ISSN: 08913668 NLM ISO Abbreviation: Pediatr Infect Dis J Subsets: MEDLINE
Subject
Language
English
Abstract
The Pneumonia Etiology Research for Child Health (PERCH) study evaluated the etiology of severe and very severe pneumonia in children hospitalized in 7 African and Asian countries. Here, we summarize the highlights of in-depth site-specific etiology analyses published separately in this issue, including how etiology varies by age, mortality status, malnutrition, severity, HIV status, and more. These site-specific results impart important lessons that can inform disease control policy implications.
Competing Interests: M.D.K. has received funding for consultancies from Merck, Pfizer, Novartis, and grant funding from Merck. L.L.H. has received grant funding from GlaxoSmithKline, Pfizer and Merck. K.L.O. has received grant funding from GlaxoSmithKline and Pfizer and participated on technical advisory boards for Merck, Sanofi-Pasteur, PATH, Affinivax and ClearPath. C.P. has received grant funding from Merck. The other authors have no funding or conflicts of interest to disclose.
(Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.)
Competing Interests: M.D.K. has received funding for consultancies from Merck, Pfizer, Novartis, and grant funding from Merck. L.L.H. has received grant funding from GlaxoSmithKline, Pfizer and Merck. K.L.O. has received grant funding from GlaxoSmithKline and Pfizer and participated on technical advisory boards for Merck, Sanofi-Pasteur, PATH, Affinivax and ClearPath. C.P. has received grant funding from Merck. The other authors have no funding or conflicts of interest to disclose.
(Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.)